IPCA Laboratories Limited
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
What IPCA files
- Others46
- Investor Meet26
- Important21
- Board Meeting11
- Updates9
- Dividend/Bonus8
Ipca Labs is informing shareholders without registered emails about Annual Report access. Its 76th AGM is on Aug 13, 2026. Shareholders are reminded to update KYC, as incomplete details could restrict future dividend and other payments.
Ipca Labs achieved major FY26 sustainability targets: 13.5% Scope 1&2 emissions intensity reduction, 50.8% hazardous waste diversion (exceeding target), and 20.59% women in offices. Water consumption dropped; 15 plants have Zero Liquid Discharge. However, customer complaints and 9 voluntary product recalls rose, posing operational challenges.
Ipca Laboratories issued a revised passcode link for its conference call to discuss Q4FY26 earnings and a business update. This call offers investors insights into the company's recent financial performance and strategic developments.
Ipca Labs submitted a routine report on re-lodgement requests for physical shares for November and December. This is a compliance update with no material operational or financial implications.
Ipca Laboratories sold its non-operational US step-down subsidiary, Bayshore Pharma, for $400,000 (approx. 3.3 Cr) to Centaur Pharma USA Inc., reducing compliance costs. The company is also updating its registered office address for easier project filings.